ROSLYN CHAISANGUANTHUM, M.D.
Hematology & Oncology Physician in SYLMAR, California. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
ROSLYN CHAISANGUANTHUM, M.D. filed 1,307 Medicare Part D claims in 2023 as a Hematology & Oncology Physician in SYLMAR, California.
- 1K
- Part D claims, 2023
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
ROSLYN CHAISANGUANTHUM, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023 — across all CMS prescribers nationally
1,307 Top 21% higher than 79% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
ROSLYN CHAISANGUANTHUM, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about ROSLYN CHAISANGUANTHUM, M.D.?
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in California
How Hematology & Oncology Physician compares to other specialties among California providers
Hematology & Oncology Physician share within California
Hematology & Oncology Physician is one of the more visible NUCC categories in California
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Specialty board-certification context
Estimated specialty board-certified rate — Hematology & Oncology Physician (ABMS / AOA reference)
- Est. board-certified rate
- 78%
- Hematology & Oncology Physician ABMS/AOA estimate
Est. board-certified rate (Hematology & Oncology Physician) — ABMS / AOA estimate
Verify credentials
- Verify via ABMS free public lookup
- Verify via AOA osteopathic boards
- Specialty volume Hematology & Oncology Physician US NPIs
Specialty board-certified rate — Hematology & Oncology Physician estimate
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus Maintenance of Certification cycles. CMS does not publish a per-provider board-certification field; the figure shown is the specialty-level estimated rate from ABMS / AOA reference data.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
ROSLYN CHAISANGUANTHUM, M.D. appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D. credentials at 14445 OLIVE VIEW DR, SYLMAR, CA, 91342, with a listed phone of (818) 364-3205. NPI 1174726954 was issued on 06/07/2007. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what CHAISANGUANTHUM most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 1,307 prescription claims written by this provider, covering 239 Medicare beneficiaries and totaling roughly $4.8 million in drug spend, with an opioid prescribing rate of 3.9%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.
Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1174726954 |
|---|---|
| Specialty | Hematology & Oncology Physician |
| Credentials | M.D. |
| Gender | Female |
| NPI Issued | 06/07/2007 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm ROSLYN CHAISANGUANTHUM, M.D.'s current license status, disciplinary history, and board certifications with the Medical Board of California in California before relying on this page for a clinical or care decision.
How we sourced this profile
Hospital and facility affiliations
Facilities where ROSLYN CHAISANGUANTHUM, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
License & disciplinary context — California MBC 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 — they are NOT specific to ROSLYN CHAISANGUANTHUM, M.D.. To verify ROSLYN CHAISANGUANTHUM, M.D.'s current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 2,257
- Total Day Supply
- 61,625
- Generic Drug Cost
- $604K
- Opioid Claims
- 51 (3.9% rate)
Patient Demographics
- Average Patient Age
- 74.7 years
- Avg HCC Risk Score
- 1.85
- Gender Split
- 75% female / 25% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What ROSLYN CHAISANGUANTHUM, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Letrozole
Letrozole
251 claims
- Dexamethasone
Dexamethasone
125 claims
- Anastrozole 64
Anastrozole
64 claims
- Prednisone 55
Prednisone
55 claims
- Ibrance 48
Ibrance
48 claims
- Abiraterone Acetate 47
Abiraterone Acetate
47 claims
- Lenalidomide 45
Lenalidomide
45 claims
- Prochlorperazine M… 40
Prochlorperazine Maleate
40 claims
| Drug | Claims |
|---|---|
| Letrozole | 251 |
| Dexamethasone | 125 |
| Anastrozole | 64 |
| Prednisone | 55 |
| Ibrance Palbociclib | 48 |
| Abiraterone Acetate | 47 |
| Lenalidomide | 45 |
| Prochlorperazine Maleate | 40 |
| Tagrisso Osimertinib Mesylate | 40 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 39 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Hematology & Oncology Physician Overview
How ROSLYN CHAISANGUANTHUM, M.D. fits within the Hematology & Oncology Physician landscape nationally.
ROSLYN CHAISANGUANTHUM, M.D.'s 1,307 claims are above the specialty average of 847.
Nearby Hematology & Oncology Physician Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as CHAISANGUANTHUM.
Compare Hematology & Oncology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore California
Frequently Asked Questions
What is ROSLYN CHAISANGUANTHUM, M.D.'s specialty? ▼
How much does ROSLYN CHAISANGUANTHUM, M.D. prescribe under Medicare Part D? ▼
Where is ROSLYN CHAISANGUANTHUM, M.D. located? ▼
What is ROSLYN CHAISANGUANTHUM, M.D.'s NPI number? ▼
Does ROSLYN CHAISANGUANTHUM, M.D. prescribe opioids? ▼
How many Hematology & Oncology Physician providers are there in the US? ▼
What drugs does ROSLYN CHAISANGUANTHUM, M.D. prescribe most often? ▼
Does ROSLYN CHAISANGUANTHUM, M.D. accept Medicare? ▼
How can I verify ROSLYN CHAISANGUANTHUM, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology